Table 2.
Alternative AAT reference ranges by genotype based on data from a large US screening program,48 with reference ranges from the 2003 ATS/ERS statement6 for comparison.
| Normal range | ||||
| Genotype | PI*MM | |||
| AAT levels: mg/dL (µM) | Sanders et al.48† | 126.9–159.2 (23–29) | ||
| ATS/ERS statement | 150–350 (27–64) | |||
| Intermediate deficiency genotypes | ||||
| Genotype | PI*MS | PI*SS | PI*MZ | |
| AAT levels: mg/dL (µM) | Sanders et al.48† | 105.0–131.4 (19–24) | 88.2–107.5 (16–20) | 75.8–96.6 (14–18) |
| ATS/ERS statement | Not provided | 100–200 (18–37) | 90–210 (17–39) | |
| Severe deficiency genotypes | ||||
| Genotype | PI*ZF | PI*SZ | PI*ZZ | |
| AAT levels: mg/dL (µM) | Sanders et al.48† | 64.5–79.2 (12–15) | 46.4–61.0 (8–11) | 0–28.2‡ (0–5) |
| ATS/ERS statement | Not provided | 75–120 (13–22) | 20–45 (3–8) | |
†
Data are interquartile ranges of AAT levels (measured by immunoturbidimetry) from individuals with normal CRP levels (CRP < 5 mg/dL).
‡
lower quartile was below the assay detection limit of 20 mg/dL.
AAT, alpha-1 antitrypsin; ATS, American Thoracic Society; CRP, C-reactive protein; ERS, European Respiratory Society; PI, protease inhibitor.